OBJECTIVES: To identify which is the alternative that minimizes costs in the treatment of Rheumatoid Arthritis with biological therapy in Mexico. METHODS: A cost minimization evaluation was done, comparing alternatives considered comparable in effectiveness in the management of RA in adult patients (Infliximab, Etanercept and Adalimumab, Rituximab, Tocilizumab) in a 9-year horizon. Since the frequency of retreatment with Rituximab hasn´t been standarized, the assumption of the retreatment scheme of every 9 months as the average of the standards was taken in account. Costs are expressed in US dollars. RESULTS: The total cost for 9 years with Rituximab was the lowest ($ 74,040), followed by Tocilizumab ($ 75,328), Etanercept ($ 76,034), Adalimumab ($ 89,490) and Infliximab ($ 91,543), generating savings with Rituximab of $ 1,288, $ 1,994, $ 15,450 and $ 17,503 respectively. Likewise, Rituximab was the alternative with the lowest number of applications (26), compared with Tocilizumab (117), Etanercept (468), infliximab (60) and Adalimumab (234). In the budget impact analysis, assuming that 100% of the patients are treated with Rituximab, the health facility could generate savings and therefore could gain access to biological therapy to more patients tan if they were treated under a scheme without Rituximab. The results of the sensitivity analysis, taking as a variable number of applications of Rituximab year showed, with an 85.44% of probability, that rituximab is shown to be the least costly alternative compared with Infliximab; 74.09% compared with Adalimumab; 53.17% compared with Etanercept, and with 51.38%, Rituximab is also less expensive compared to Tocilizumab CONCLUSIONS: Rituximab proved to be an alternative that minimizes costs, generating savings and allowing greater access to therapy for patients with RA, offering benefits to health institutions, not only improving the quality of care with an innovative therapy, but also allowing significant cost savings.